Measuring the activity of apixaban and rivaroxaban with rotational thrombelastometry

Thrombosis Research

Volumn 134, Issue 4, 2014, Pages 918-923

  Adelmann, Dieter ^a   Wiegele, Marion ^a   Wohlgemuth, Rudolf Karl ^a   Koch, Stefan ^a   Frantal, Sophie ^a   Quehenberger, Peter ^a   Scharbert, Gisela ^a   Kozek Langenecker, Sibylle ^b   Schaden, Eva ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Department of Anaesthetics and Intensive Care   (Austria)

Author keywords

Apixaban; Blood coagulation tests; Point of Care coagulation tests; Rivaroxaban; Thrombelastography

Indexed keywords

APIXABAN; BLOOD CLOTTING FACTOR 10A; RIVAROXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; THIOPHENE DERIVATIVE;

ANALYZER; ARTICLE; BLOOD CLOTTING TEST; BLOOD CLOTTING TIME; BLOOD COLLECTION TUBE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG MONITORING; HUMAN; HUMAN TISSUE; POINT OF CARE TESTING; ROTATIONAL THROMBELASTOMETRY; THROMBOELASTOGRAPHY; BLOOD; BLOOD CLOTTING; DRUG EFFECTS; HOSPITAL INFORMATION SYSTEM; PROCEDURES;

BLOOD COAGULATION; FACTOR XA INHIBITORS; HUMANS; MORPHOLINES; POINT-OF-CARE SYSTEMS; PYRAZOLES; PYRIDONES; THIOPHENES; THROMBELASTOGRAPHY;

EID: 84908137739     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.08.006     Document Type: Article

References (25)

1. Mani H, Kasper A, Lindhoff-Last E. Measuring the anticoagulant effects of target specific oral anticoagulants-reasons, methods and current limitations. J Thromb Thrombolysis 2013;36:187-94.
2. Garcia D, Barrett YC, Ramacciotti E, Weitz JI. Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants. J Thromb Haemost 2013;11:245-52.
3. Lindhoff-Last E, Samama MM, Ortel TL, Weitz JI, Spiro TE. Assays for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit 2010;32:673-9.
4. Mani H, Rohde G, Stratmann G, Hesse C, Herth N, Schwers S, et al. Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin. Thromb Haemost 2012;108:191-8.
5. Kozek-Langenecker S. Management of massive operative blood loss. Minerva Anestesiol 2007;73:401-15.
6. Casutt M, Konrad C, Schuepfer G. Effect of rivaroxaban on blood coagulation using the viscoelastic coagulation test ROTEM™. Anaesthesist 2012;61:948-53.
7. Schaden E, Schober A, Hacker S, Spiss C, Chiari A, Kozek-Langenecker S. Determination of enoxaparin with rotational thrombelastometry using the prothrombinase-induced clotting time reagent. Blood Coagul Fibrinolysis 2010;21:256-61.
8. Schaden E, Jilch S, Hacker S, Schober A, Kozek-Langenecker S. Monitoring of unfractionated heparin with rotational thrombelastometry using the prothrombinase-induced clotting time reagent (PiCT®). Clin Chim Acta 2012;414:202-5.
9. Sørensen B, Johansen P, Christiansen K, Woelke M, Ingerslev J. Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation. J Thromb Haemost 2003;1:551-8.
10. Calatzis A, Peetz D, Haas S, Spannagl M, Rudin K, Wilmer M. Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors. Am J Clin Pathol 2008;130:446-54.
11. Österreichische Gesellschaft für Anaesthesiologie Reanimation und Intensivmedizin. Bleeding history - Recommendations of the working group on Perioperative Coagulation of the ÖGARI. [Internet] Vienna (Austria): ÖGARI; July 1 2007 [cited 2013 Sept 1. Available from: http://www.oegari.at/web-files/dateiarchiv/116/Recommendation%20bleeding%20history%202007.pdf].
12. Frost C, Wang J, Nepal S, Schuster A, Barrett YC, Mosqueda-Garcia R, et al. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol 2013;75:476-87.
13. Mueck W, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, et al. Population pharmacokinetics and pharmacodynamics of onceand twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 2007;97:931-7.
14. European Medicines Agency. Eliquis : EPAR - Product Information. [Internet] London (UK): European Medicines Agency; Jun 20 2011 [updated 2013 Mai 13; cited 2013 Sept 1. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/002148/WC500107728.pdf].
15. Perzborn E, Roehrig S, Straub A, Kubitza D, Mueck W, Laux V. Rivaroxaban: A New Oral Factor Xa Inhibitor. Arterioscler Thromb Vasc 2010;30:376-81.
16. Samama MM, Amiral J, Céline G, Perzborn E, Depasse F. Specific and rapid measurement of rivaroxaban in plasma using a new, dedicated chromogenic assay. Hamostaseologie 2010;30:A37.
17. Kozek-Langenecker SA, Afshari A, Albaladejo P, Santullano CAA, De Robertis E, Filipescu DC, et al. Management of severe perioperative bleeding. Eur J Anaesthesiol 2013;30:270-382.
18. Samama MM, Martinoli JL, LeFlem L, Guinet C, Plu-Bureau G, Depasse F, et al. Assessment of laboratory assays to measure rivaroxaban - an oral, direct factor Xa inhibitor. Thromb Haemost 2010;103:815-25.
19. Samama MM, Contant G, Spiro TE, Perzborn E, Guinet C, Gourmelin Y, et al. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 2012;107:379-87.
20. Haas T, Spielmann N, Mauch J, Madjdpour C, Speer O, Schmugge M. Weiss M. Comparison of thromboelastometry (ROTEM®) with standard plasmatic coagulation testing in paediatric surgery. Br J Anaesth 2012;108:36-41.
21. Kluft C, Meijer P, Kret R, Burggraaf J. Preincubation in the Prothrombinase-induced Clotting Time test (PiCT) is necessary for in vitro evaluation of fondaparinux and to be avoided for the reversible, direct factor Xa inhibitor, rivaroxaban. Int J Lab Hematol 2013;35:379-84.
22. Harder S, Parisius J, Picard-Willems B. Monitoring direct FXa-inhibitors and fondaparinux by Prothrombinase-induced Clotting Time (PiCT): relation to FXa-activity and influence of assay modifications. Thromb Res 2008;123:396-403.
23. Graff J, Picard-Willems N, Harder S.Monitoring effects of direct FXa-inhibitors with a new One-Step Prothrombinase- induced Clotting Time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux, and DX 9065a. Int J Clin Pharmacol Ther 2007;45:234.
24. Douxfils J, Mullier F, Loosen C, Chatelain C, Chatelain B, Dogné JM. Assessment of the impact of rivaroxaban on coagulation assays: Laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thromb Res 2012;130:956-66.
25. Molenaar PJ, Dinkelaar J, Leyte A. Measuring Rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generation. Clin Chem Lab Med 2012;50:1799-807.